Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 10/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.48 |
| ▸ | MEN1 | O00255 | 8/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 7/20 | 0.47 |
| ▸ | HTT | P42858 | 5/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6680116 | 1.00 | CA1 (0.53) | CA1CA2CA9KAT8MAPT | |
| SCHEMBL14197585 | 1.00 | CA1 (0.53) | CA1CA2CA9KAT8MAPT | |
| SCHEMBL6679978 | 1.00 | CA1 (0.53) | CA1CA2CA9KAT8MAPT | |
| SCHEMBL13763582 | 0.96 | KAT8 (0.48) | CA1CA2CA9KAT8MAPT | |
| SCHEMBL4825033 | 0.96 | KAT8 (0.48) | CA1CA2CA9KAT8MAPT | |
| SCHEMBL6680125 | 0.96 | KAT8 (0.48) | CA1CA2CA9KAT8MAPT | |
| SCHEMBL3188484 | 0.96 | KAT8 (0.48) | CA1CA2CA9KAT8MAPT | |
| SCHEMBL6678634 | 0.95 | KAT8 (0.48) | CA1CA2CA9KAT8MAPT | |
| SCHEMBL6678627 | 0.95 | KAT8 (0.48) | CA1CA2CA9KAT8MAPT | |
| SCHEMBL6679975 | 0.91 | CA1 (0.52) | CA1CA2CA9KAT8MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035187-A1 | ANTI-NEURODEGENERATIVE DISEASE AGENT | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120035187-A1 | ANTI-NEURODEGENERATIVE DISEASE AGENT | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035187-A1 | ANTI-NEURODEGENERATIVE DISEASE AGENT | SNCA, PSEN1, CDR2 | CA1 1468/4885CA2 2334/4885CA9 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.